Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PD-1

PD-1

Brief Information

Name:Programmed cell death protein 1
Target Synonym:Programmed cell death protein 1,CD279,hPD-1,PDCD1,Programmed Cell Death 1,Systemic Lupus Erythematosus Susceptibility 2,Protein PD-1,PD1,Programmed Cell Death 1 Protein,CD279 Antigen,HPD-L,HSLE1,SLEB2,PD-1,Programmed Cell Death 1 Receptor
Number of Launched Drugs:16
Number of Drugs in Clinical Trials:150
Lastest Research Phase:Approved

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
PD-1 VHH mAb - 01 PCC Solid Tumor Solid tumor

Licensing

Project Name Modality Therapeutic Area Indications Stage Right Available
SIRPα×PD-1 bsAb Bispecific antibody Oncology/Cancer Advanced solid tumor Preclinical Global
PD-1×TIGIT BsAb for Advanced solid tumor Bispecific antibody Oncology/Cancer Cancer Preclinical Global
SN-38 Polymeric Nanoparticle (new formulation) Small molecule Oncology/Cancer Solid tumor,Lung cancer Phase II Global

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
CHEK-ATP143 Human HEK293/Human PD-1 Stable Cell Line
PD1-M82E3 Mouse Biotinylated Mouse PD-1 / PDCD1 Protein, His,Avitag™ (MALS verified)
PD1-M82E3-structure
PD1-M82E3-sds
PD1-M5257 Mouse Mouse PD-1 / PDCD1 Protein, Mouse IgG2a Fc Tag (MALS verified)
PD1-M5257-structure
PD1-M5257-sds
EP-163 Human PD-1 : PD-L1 [Biotinylated] Inhibitor Screening ELISA Kit-Pre coated plate
PD1-C82F7 Cynomolgus Biotinylated Cynomolgus PD-1 / PDCD1 Protein, Fc,Avitag™ (MALS verified)
PD1-C82F7-structure
PD1-C82F7-sds
HGS-S238 Mouse Recombinant Monoclonal Anti-PD-1 Antibody, Mouse (2F3)
PD1-H5286 Human Human PD-1 / PDCD1 Protein, Twin-Strep Tag (MALS verified)
PD1-H5286-structure
PD1-H5286-sds
EP-154 Human PD-1 : PD-L2 [Biotinylated] Inhibitor Screening ELISA Kit
SCJUR-STF064 Human Human PD-1 (Luc) Jurkat Reporter Cell Development Service
PD1-C52H5 Cynomolgus Cynomolgus PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-C52H5-structure
PD1-C52H5-sds
RAB-P002 Human Human Anti-PD-1 Antibody IgG Titer Serologic ELISA Assay Kit
PD1-C52E5 Canine Biotinylated Canine PD-1 / PDCD1 Protein, His,Avitag™
PD1-C52E5-structure
PD1-C52E5-sds
EP-120 Human PD-1 [Biotinylated] : PD-L2 Inhibitor Screening ELISA Kit
EP-130 Human PD-1 : PD-L1 [Biotinylated] Inhibitor Screening ELISA Kit
PD1-H5256 Human Human PD-1 / PDCD1 Protein, Fc,His Tag
PD1-H5256-structure
PD1-H5256-sds
PD1-H52H2 Human Human PD-1 Protein, His Tag (Nanoparticle)
PD1-H52H2-sds
PD1-C52H9 Canine Canine PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-C52H9-structure
PD1-C52H9-sds
PD1-H82A4 Human Biotinylated Human PD-1 / PDCD1 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
PD1-H82A4-structure
PD1-H82A4-sds
PD1-R52H3 Rhesus macaque Rhesus macaque PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-R52H3-structure
PD1-R52H3-sds
PD1-H52H6 Human Human PD-1 / PDCD1 Full Length Protein, His Tag
PD1-H52H6-structure
PD1-H52H6-sds
PD1-H82F4 Human Biotinylated Human PD-1 / PDCD1 Protein, Fc,Avitag™,His Tag (MALS verified)
PD1-H82F4-structure
PD1-H82F4-sds
PD1-C82E6 Cynomolgus Biotinylated Cynomolgus PD-1 / PDCD1 Protein, His,Avitag™
PD1-C82E6-structure
PD1-C82E6-sds
PD1-HP2F2 Human PE-Labeled Human PD-1 / PDCD1 Protein, Fc,His Tag (recommended for neutralizing assay)
PD1-HP2F2-structure
PD1-H5255 Human Human PD-1 / PDCD1 Protein, Mouse IgG2a Fc Tag (HPLC-verified)
PD1-H5255-structure
PD1-H5255-sds
PD1-H5255-hplc
PD1-H522a Human Human PD-1 / PDCD1 Protein, His Tag, low endotoxin (MALS verified)
PD1-H522a-structure
PD1-H522a-sds
EPC-V1 Monkey ELISA Assay Kit for Anti-PD-1 h-mAb in Monkey Serum
EPM-V1 Mouse ELISA Assay Kit for Anti-PD-1 h-mAb in Mouse Serum
PD1-H5259 Human Human PD-1 / PDCD1 Protein, Llama IgG2b Fc Tag, low endotoxin
PD1-H5259-structure
PD1-H5259-sds
EPH-V1 Human ELISA Assay Kit for Anti-PD-1 h-mAb in Human Serum
PD1-H82F1 Human Biotinylated Human PD-1 / PDCD1 Protein, Fc,Avitag™ (MALS verified)
PD1-H82F1-structure
PD1-H82F1-sds
PD1-RB5251 Rabbit Rabbit PD-1 / PDCD1 Protein, Fc Tag
PD1-RB5251-structure
PD1-RB5251-sds
PD1-R52H2 Rat Rat PD-1 / PDCD1 Protein, His Tag
PD1-R52H2-structure
PD1-R52H2-sds
PD1-H82E4 Human Biotinylated Human PD-1 / PDCD1 Protein, Avitag™,His Tag (recommended for biopanning) (MALS verified)
PD1-H82E4-structure
PD1-H82E4-sds
PD1-R52H0 Rabbit Rabbit PD-1 / PDCD1 Protein, His Tag (MALS verified)
PD1-R52H0-structure
PD1-R52H0-sds
PD1-M82F4 Mouse Biotinylated Mouse PD-1 / PDCD1 Protein, Fc,Avitag™ (MALS Verified)
PD1-M82F4-structure
PD1-M82F4-sds
PD1-R5253 Rat Rat PD-1 / PDCD1 Protein, Fc Tag
PD1-R5253-structure
PD1-R5253-sds
PD1-M5259 Mouse Mouse PD-1 / PDCD1 Protein, Fc Tag
PD1-M5259-structure
PD1-M5259-sds
PD1-H5284 Human Human PD-1 / PDCD1 Protein, Twin-Strep Tag (MALS verified)
PD1-H5284-structure
PD1-H5284-sds
PD1-M5228 Mouse Mouse PD-1 / PDCD1 Protein, His Tag
PD1-M5228-structure
PD1-M5228-sds
PD1-C5254 Cynomolgus Cynomolgus PD-1 / PDCD1 Protein, Fc Tag (MALS verified)
PD1-C5254-structure
PD1-C5254-sds
PD1-H5257 Human Human PD-1 / PDCD1 Protein, Fc Tag, low endotoxin (MALS Verified)
PD1-H5257-structure
PD1-H5257-sds
PD1-H5221 Human Human PD-1 / PDCD1 Protein, His Tag (MALS Verified)
PD1-H5221-structure
PD1-H5221-sds
ACRO Quality

Part of Bioactivity data

CHEK-ATP143-Cell-based assay
 PD-1 FACS

Fig. FACS analysis of PD-1 on HEK293/Human PD-1 Stable Cell Line.
FACS assay shows that Human PD-L1 Protein, Mouse IgG1 Fc Tag can bind to HEK293/Human PD-1 Stable Cell Line. HEK293/Human PD-1 Stable Cell Line was red line, negative control HEK293 cells was grey line(QC tested).

SCJUR-STF064-Cell-based assay
 PD-1 FACS

Expression analysis of human PD-1 on Human PD-1 (Luc) Jurkat Reporter Cell by FACS.
Human PD-1 (Luc) Jurkat Reporter Cell or negative control cell were stained with FITC-labeled anti-human PD1 antibody.

PD1-R52H0-SPR
Human_FcRn_Heterodimer_Protein_SPR

Rabbit PD-L1, His Tag (Cat. No. PDL-R52H6) immobilized on CM5 Chip can bind Rabbit PD-1, His Tag (Cat. No. PD1-R52H0) with an affinity constant of 3.87 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

PD1-M5259-SPR
 PD-1 SPR

Captured Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) on Protein A Chip can bind Mouse PD-L1, His Tag (Cat. No. PD1-M5220) with an affinity constant of 2.16 μM as determined in SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

PDCD1,PD1,CD279,SLEB2

Background

How a therapeutic antibody is metabolized in the body is pertinently relevant to its efficacy. Therefore, pharmacokinetics study is an important part of the drug development. PD-1 is probably the most targeted molecule in today’s pharmaceutical industry, thanking to the clinical success of Keytruda® and Opdivo®. Many investigational anti-PD-1 mAbs are being developed. There is a growing need for a standard assay that can be used to facilitate the study of their pharmacokinetics.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Prolgolimab BCD-100 Approved Biocad Forteca Russian Federation Melanoma Biocad 2020-04-01 Carcinoma, Renal Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms Details
Sintilimab IBI-308 Approved Innovent Biologics(Suzhou) Co Ltd Tyvyt, 达伯舒 Mainland China Stomach Neoplasms Innovent Biologics(Suzhou) Co Ltd 2018-12-24 Sarcoma; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Neoplasms, Unknown Primary; Lymphoma, Non-Hodgkin; Lung Neoplasms; Carcinoma, Neuroendocrine; Colorectal Neoplasms; Lymphoma, Extranodal NK-T-Cell; Solid tumours; Lung Diseases; Respiratory Tract Diseases; Hodgkin Disease; Nasopharyngeal Neoplasms; Neoplasms; Thoracic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Lymphoma, T-Cell, Peripheral Details
Pucotenlimab AK-103; HX-008 Approved Taizhou Hanzhong Biomedical Co Ltd, Hanx Biopharmaceutical Co Ltd, Zhongshan Akeso Biopharma Co Ltd, Lepu Biotech Co Ltd 普佑恒 Mainland China Melanoma Lepu Biotech Co Ltd 2022-07-19 Solid tumours; Mismatch Repair Deficient Cancer; Esophageal Neoplasms; Stomach Neoplasms; Thyroid Carcinoma, Anaplastic; Triple Negative Breast Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Colorectal Neoplasms; Melanoma; Adenocarcinoma; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Penpulimab AK-105 Approved Zhongshan Akeso Biopharma Co Ltd 安尼可 Mainland China Hodgkin Disease Zhengda Tianqing Kangfang (Shanghai) Biomedical Technology Co Ltd 2021-08-03 Neuroendocrine Tumors; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Lung Neoplasms; Urologic Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Microsatellite instability-high cancer; Hodgkin Disease; Neoplasms; Esophageal Neoplasms; Thoracic Neoplasms; Head and Neck Neoplasms; Liver Neoplasms Details
Cadonilimab AK-104 Approved Zhongshan Akeso Biopharma Co Ltd 开坦尼 Mainland China Uterine Cervical Neoplasms Kangfang Pharmaceutical Co Ltd 2022-06-29 Nasopharyngeal Carcinoma; Melanoma; Carcinoma, Hepatocellular; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Urologic Neoplasms; Colorectal Neoplasms; DNA Repair-Deficiency Disorders; Microsatellite Instability; Lymphoma, T-Cell, Peripheral; Microsatellite instability-high cancer; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours Details
Zimberelimab AB-122; GLS-010; WBP-3055 Approved Harbin Gloria Pharmaceuticals Co Ltd, Wuxi Biologics (Shanghai) Co Ltd 誉妥 Mainland China Hodgkin Disease Guangzhou Yuheng Biotechnology Co Ltd 2021-08-25 Urinary Bladder Neoplasms; Adenocarcinoma; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Lymphoma, Non-Hodgkin; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Lung Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Pancreatic Neoplasms; Glioblastoma; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; Liver Neoplasms Details
Toripalimab JS-001sc; TAB-001; JS-001; SO-001 Approved Shanghai Junshi Biosciences Co Ltd, Suzhou Union Biopharm Biosciences Co Ltd 拓益 Mainland China Carcinoma, Non-Small-Cell Lung Shanghai Junshi Biosciences Co Ltd 2018-12-17 Lymphoma; Urinary Bladder Neoplasms; Rejection of organ transplantation; Nasopharyngeal Carcinoma; Breast Neoplasms; Sarcoma; Cholangiocarcinoma; Urologic Neoplasms; Colorectal Neoplasms; Neuroendocrine Tumors; Esophageal Squamous Cell Carcinoma; Epstein-Barr Virus Infections; Laryngeal Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Stomach Neoplasms; Solid tumours; Colorectal Neoplasms, Hereditary Nonpolyposis; Head and Neck Neoplasms; Biliary Tract Neoplasms; Esophageal Neoplasms; Anus Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Kidney Neoplasms; Pain; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Nasopharyngeal Neoplasms; Nasopharyngeal Diseases; Hypopharyngeal Neoplasms Details
Nivolumab MDX-1106; ONO-4538; ono-0123; BMS-936558; BMS-936558-01 Approved Bristol-Myers Squibb Company, Ono Pharmaceutical Co Ltd Opdivo, 欧狄沃 Japan Carcinoma, Transitional Cell Ono Pharmaceutical Co Ltd 2014-07-04 Liver Neoplasms; Leiomyosarcoma; Solid tumours; Bone Marrow Neoplasms; Lymphoma, T-Cell, Peripheral; Hematologic Neoplasms; Acquired Immunodeficiency Syndrome; Tobacco Smoking; Head and Neck Neoplasms; Biliary Tract Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Ependymoma; Medulloblastoma; Hematopoietic stem cell transplantation (HSCT); Kidney Neoplasms; Drug-Related Side Effects and Adverse Reactions; Ovarian Neoplasms; HIV Infections; Esophageal Neoplasms; Stomach Neoplasms; Polycythemia Vera; Carcinoma, Renal Cell; Giant Cell Arteritis; Squamous Cell Carcinoma of Head and Neck; Leukoplakia, Oral; Mismatch Repair Deficient Cancer; Leukemia, Lymphoid; Rectal Neoplasms; Anus Neoplasms; Inflammatory Bowel Diseases; Dermatomyositis; Thoracic Neoplasms; Carcinoma, Merkel Cell; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Neoplasms; HTLV-I Infections; Enteropathy-Associated T-Cell Lymphoma; Hodgkin Disease; Myelodysplastic Syndromes; Adrenal Cortex Neoplasms; Glioblastoma; Arthritis, Rh Details
Cemiplimab SAR-439684; REGN-2810 Approved Regeneron Pharmaceuticals Inc Libtayo EU Uterine Cervical Neoplasms Regeneron Ireland Designated Activity Company 2018-09-28 Sarcoma; Mycosis Fungoides; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Mouth Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Diffuse Intrinsic Pontine Glioma; Peritoneal Neoplasms; Hepatitis B; Prostatic Neoplasms; Solid tumours; Central Nervous System Neoplasms; Multiple Myeloma; Skin Neoplasms; Carcinoma, Transitional Cell; Papillomavirus Infections; Hodgkin Disease; Neoplasms; Carcinoma, Merkel Cell; Hemangiosarcoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; HIV Infections; Ovarian Neoplasms Details
Tislelizumab BGB-A317; VDT-482 Approved Beigene Ltd 百泽安 Mainland China Nasopharyngeal Carcinoma Beigene Guangzhou Biologics Manufacturing Co Ltd 2019-12-26 Lymphoma, T-Cell, Cutaneous; Digestive System Neoplasms; Nasopharyngeal Carcinoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Extranodal NK-T-Cell; Cholangiocarcinoma; Colorectal Neoplasms; Thymoma; Esophageal Squamous Cell Carcinoma; Lymphoma, Large-Cell, Anaplastic; Urinary Bladder Neoplasms; Lymphoma, T-Cell; Lymphoma; Lung Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Rectal Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell, Peripheral; Leukemia; Liver Neoplasms; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Mismatch Repair Deficient Cancer; Solid tumours; Anus Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Neoplasms; Small Cell Lung Carcinoma; Mesothelioma; Microsatellite instability-high cancer Details
Camrelizumab SHR-1210; INCSHR-1210; HR-301210 Approved Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd AiRuiKa, 艾瑞卡, 艾立妥 Mainland China Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Suzhou Suncadia Biopharmaceuticals Co Ltd 2019-05-29 Carcinoma, Squamous Cell; Cholangiocarcinoma; Lymphoma, Extranodal NK-T-Cell; Respiratory Tract Neoplasms; Breast Neoplasms; Urologic Neoplasms; Genital Neoplasms, Female; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Lymphoma; Lung Neoplasms; Endometrial Neoplasms; Nasopharyngeal Carcinoma; Paranasal Sinus Neoplasms; Esophageal adenocarcinoma; Uterine Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms; Melanoma; Uterine Cervical Neoplasms; Esophageal Diseases; Triple Negative Breast Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Carcinoma, Bronchogenic; Hemorrhagic Fever, Ebola; Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Bronchial Neoplasms; Thoracic Neoplasms; Hodgkin Disease; Solid tumours; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Nasopharyngeal Neoplasms; Hypopharyngeal Neoplasms; Respiratory Tract Diseases; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Urinary Bladder Details
Dostarlimab WBP-285; TSR-042; ANB-011 Approved Anaptysbio Inc JEMPERLI United States Solid tumours Glaxosmithkline Llc 2021-04-21 Sarcoma, Clear Cell; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Lung Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Solid tumours; Breast Neoplasms; Gestational Trophoblastic Disease; Mesothelioma; Colonic Neoplasms; Pancreatic Neoplasms; Neoplasms; Rectal Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms Details
Pembrolizumab SCH-900475; h409A11; MK-3475 Approved Merck & Co Inc 可瑞达, Keytruda Mainland China Triple Negative Breast Neoplasms Moshadong R & D (China) Co Ltd 2014-09-04 Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms; Ependymoma; Lymphoma, B-Cell; Solitary Fibrous Tumor, Pleural; Kidney Neoplasms; Medulloblastoma; Lymphoma, B-Cell, Marginal Zone; Biliary Tract Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Neoplasm Recurrence, Local; Lymphoma, T-Cell, Peripheral; Erythema; Neoplasm, Residual; HIV Infections; Bone metastases; Protein Deficiency; Intestinal Neoplasms; Leiomyosarcoma; Ovarian germ cell tumor; Hematologic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Spinal Cord Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Anus Neoplasms; Carcinoma, Merkel Cell; Vaginal Diseases; Carcinoid Tumor; Polycythemia Vera; Mismatch Repair Deficient Cancer; Vaginitis; Cystadenocarcinoma, Serous; Genital Neoplasms, Male; Pheochromocytoma; Rectal Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Hodgkin Disease; Details
Nivolumab/Relatlimab BMS-986213; BMS-936558/BMS-986016 Approved Bristol-Myers Squibb Company OPDUALAG EU Melanoma Bristol-Myers Squibb Pharma Eeig 2022-03-18 Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Colorectal Neoplasms; Melanoma Details
Serplulimab HLX-10 Approved Shanghai Henlius Biotech Co Ltd 汉斯状 Mainland China Microsatellite instability-high cancer Shanghai Henlius Biopharmaceuticals Co Ltd 2022-03-22 Triple Negative Breast Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Microsatellite Instability; Microsatellite instability-high cancer; Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hepatitis B, Chronic; Carcinoma; Liver Neoplasms; Head and Neck Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
RG-6279 RG-6279 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours Details
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) Phase 2 Clinical Shanghai Cell Therapy Research Institute Neoplasms Details
RB-0004 RB-0004 Phase 1 Clinical Reyoung Pharmaceutical Co Ltd Solid tumours; Lymphoma Details
89Zr-N-sucDf-pembrolizumab Phase 1 Clinical Merck & Co Inc, Umcg The University Medical Center Groningen Carcinoma, Non-Small-Cell Lung; Melanoma Details
PD-1 knockout EBV-CTL (Nanjing Medical University) Phase 2 Clinical Nanjing Medical University Stomach Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Lymphoma Details
STW204 STW-204; AI025; AI-025 Phase 1 Clinical Suzhou Stainwei Biotech Inc Solid tumours; Neoplasms Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) Phase 1 Clinical Shanxi Weiqidaguangming Pharmaceutical Co Ltd Solid tumours Details
INSIX RA (Indus Biotech) Clinical Indus Biotech Pvt Ltd Arthritis, Rheumatoid; Inflammation Details
Treprilimab Clinical Sun Yat-Sen University Oropharyngeal Neoplasms Details
ABBV-1882 ABBV-1882 Phase 1 Clinical Abbvie Inc HIV Infections Details
Pembrolizumab biosimilar (biocad) BCD-201 Phase 1 Clinical Biocad Solid tumours Details
Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals) Bis-5 Phase 1 Clinical Neoplasms Details
Recombinant human anti-PD-1 monoclonal antibody(Cspc Pharmaceutical Technology ,Shijiazhuang) Phase 2 Clinical Carcinoma, Ovarian Epithelial; Bile Duct Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
SSGJ-706 SSGJ-706 Phase 1 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Solid tumours; Lymphoma Details
HerinCAR-PD1 Phase 2 Clinical Ningbo Cancer Hospital Solid tumours Details
EBV-specific TCR-T cell with anti-PD1 auto-secreted element Phase 2 Clinical Tcrcure Biopharma Ltd Squamous Cell Carcinoma of Head and Neck Details
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T Phase 2 Clinical Shanghai Cell Therapy Research Institute Solid tumours Details
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) Phase 1 Clinical Second Affiliated Hospital Of Zhejiang University School Of Medicine Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Multiple Myeloma Details
Recombinant human anti-PD-1 monoclonal antibody(Hec Biological) Phase 1 Clinical Dongguan City Hec Biological Medicine Res And Development Co Ltd Stomach Neoplasms; Esophageal adenocarcinoma Details
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) ICTCAR-014 Phase 2 Clinical Innovative Cellular Therapeutics Co Ltd Lymphoma, Non-Hodgkin Details
EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) LXF-821 Phase 1 Clinical University Of Pennsylvania, Novartis Pharma Ag Glioblastoma Details
GNR-051 GNR-051 Generium Pharmaceuticals Details
PF-07209960 PF-07209960 Phase 1 Clinical Pfizer Inc Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung Details
CD-200-AR-L CD-200-AR-L; hP-1-A-8 Phase 1 Clinical University Of Minnesota Glioblastoma Details
JS-201 JS-201 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Neoplasms Details
LBL-015 LBL-015 Phase 2 Clinical Nanjing Leads Biolabs Co Ltd Solid tumours Details
SHR-1901 SHR-1901 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd Neoplasms Details
SSI-361 LVGN-3616; SSI-361 Phase 2 Clinical Lyvgen Biopharma(HK)Ltd Neoplasms Details
CA-170 CA-170; AUPM-170 Aurigene Details
TQB-2868 TQB-2868 Phase 1 Clinical Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group Neoplasms Details
Rosnilimab ANB-030 Anaptysbio Inc Alopecia Areata Details
Peramprizumab Phase 2 Clinical Sun Yat-Sen University Nasopharyngeal Carcinoma Details
Sym-024 Sym-024; S-95024 Symphogen A/S Details
BI-1387446 C.H. Boehringer Sohn Ag & Co. Kg Details
BCD-217 BCD-217 Biocad Details
BAT-1308 BAT-1308 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours Details
CMAB-819 CMAB8-19 Phase 1 Clinical Sinomab Bioscience Ltd Squamous Cell Carcinoma of Head and Neck; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Programmed cell death 1 antibody (Sun Yat-sen University) Sun Yat-Sen University Details
Pegylated recombinant human granulocyte colony stimulating factor(Sun Yat-sen University) Phase 1 Clinical Sun Yat-Sen University Nasopharyngeal Carcinoma Details
IAP-0971 IAP-0971 Phase 2 Clinical Shenghe (China) Biopharmaceutical Co Ltd Solid tumours; Neoplasms Details
ZG-005 ZG-005 Phase 2 Clinical Suzhou Zelgen Biopharmaceuticals Co Ltd Solid tumours Details
HX-009 HX-009 Phase 2 Clinical Hanx Biopharmaceutical Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd Solid tumours; Liver Neoplasms; Stomach Neoplasms; Lymphoma Details
Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) Phase 2 Clinical Anhui Anke Biotechnology (Group) Co Ltd Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma; Lung Neoplasms Details
TY-101 TY-101; TY101 Phase 2 Clinical Tayu Huaxia Biotech Medical Group Co Ltd Solid tumours; Lymphoma Details
MiHA-loaded PD-L silenced DC vaccination (Radboud University) Phase 2 Clinical Radboud University Nijmegen Hematologic Neoplasms; Colorectal Neoplasms Details
CC-90006 C-90006; CC-90006 Phase 1 Clinical Anaptysbio Inc Autoimmune Diseases; Psoriasis Details
SI-B003 SI-B003 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma Details
Sym-021 Sym-021 Phase 1 Clinical Symphogen A/S Solid tumours; Lymphoma; Neoplasm Metastasis Details
IMU-201 IMU-201 Phase 1 Clinical Imugene Ltd Adenocarcinoma of Lung; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
EBV-Specific TCR-T Cell therapy (Xinqiao Hospital of Chongqing) Phase 2 Clinical Xinqiao Hospital, Army Medical University Squamous Cell Carcinoma of Head and Neck Details
Rituximab/Paclitaxel AR-160 Phase 1 Clinical Mayo Clinic Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Pimivalimab JTX-4014 Phase 2 Clinical Jounce Therapeutics Inc Neoplasms; Carcinoma, Non-Small-Cell Lung Details
AZD-2936 AZD-2936 Phase 2 Clinical Astrazeneca Plc Carcinoma, Non-Small-Cell Lung Details
BA1104 LY-01015; BA-1104 Phase 1 Clinical Luye Pharma Group Ltd Liver Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Mesothelioma; Urinary Bladder Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
EMB-02 EMB-02 Phase 2 Clinical Shanghai Epimab Biotherapeutics, Inc Solid tumours; Neoplasms Details
SSGJ-705 SSGJ-705 Phase 1 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Solid tumours; Neoplasms Details
Latikafusp AMG-256 Phase 1 Clinical Amgen Inc Solid tumours; Neoplasms Details
RO-7121661 RG-7769; RO-7121661 Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Lorigerlimab MGD-019; AEX1344 Phase 2 Clinical Macrogenics Inc Liver Neoplasms; Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Neoplasm Metastasis; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Recombinant human anti-PD-1 monoclonal antibody(Sumgen) SG-001; SYSA1802 Phase 2 Clinical Hangzhou Sumgen Biotechnology Co Ltd Solid tumours; Biliary Tract Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Mesothelioma; Cholangiocarcinoma; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Lymphoma; Gallbladder Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
ONCR-177 ONCR-177 Phase 1 Clinical Oncorus Inc Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma Details
Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) Phase 2 Clinical Hengrui Yuanzheng (Shanghai) Biotechnology Co Ltd Solid tumours; Liver Neoplasms; Stomach Neoplasms; Neoplasms; Liver Diseases Details
Rulonilimab F-520 Phase 3 Clinical Shandong New Time Pharmaceutical Co Ltd Solid tumours; Lymphoma, T-Cell, Peripheral; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Neurolymphomatosis; Lymphoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms Details
ONO-4685 ONO-4685 Phase 1 Clinical Merus Nv Psoriasis; Lymphoma, T-Cell Details
IBI-363 IBI-363 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms; Lymphoma Details
MK-3475A MK-3475A Phase 1 Clinical Merck Sharp & Dohme Corp Solid tumours Details
Tebotelimab PD-1 X LAG-3; MGD-013 Phase 3 Clinical Macrogenics Inc Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Adenocarcinoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Endometrial Neoplasms; Cholangiocarcinoma; Small Cell Lung Carcinoma; Liver Neoplasms; Triple Negative Breast Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Biliary Tract Neoplasms; Ovarian Neoplasms; Hematologic Neoplasms; Head and Neck Neoplasms; Solid tumours Details
Peresolimab LY-3462817 Phase 2 Clinical Eli Lilly And Company Autoimmune Diseases; Arthritis, Rheumatoid; Connective Tissue Diseases; Joint Diseases; Immune System Diseases; Psoriasis; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis Details
Finotonlimab SCT-I10A Phase 3 Clinical SinoCelltech Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Recombinant human PD-1 antibody herpes simplex virus Phase 1 Clinical Yangsheng Tang Co Ltd, Xiamen University Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Neoplasms; Pancreatic Neoplasms; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Brain metastases; Lung Neoplasms; Melanoma; Uterine Cervical Neoplasms Details
Izuralimab XmAb-23104; XmAb-104 Phase 1 Clinical Xencor Inc Nasopharyngeal Carcinoma; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Breast Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms Details
AK-129 AK-129 Phase 1 Clinical Zhongshan Akeso Biopharma Co Ltd Neoplasms Details
MAX-10181 MAX-10181; MAX-1 Phase 1 Clinical Guangzhou Maxinovel Pharmaceiticals Co Ltd Solid tumours; Neoplasms Details
Budigalimab ABBV-181 Phase 2 Clinical Abbvie Inc Solid tumours; HIV Infections; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
QL1604 QL1604; QL-1604 Phase 3 Clinical Qilu Pharmaceutical Co Ltd Liver Neoplasms; Solid tumours; Neoplasms; Uterine Cervical Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular Details
Taminadenant NIR-178; PBF-509 Phase 2 Clinical Palobiofarma Sl Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Carcinoma; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Parkinson Disease; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma Details
PE0105 PE-0105 Phase 1 Clinical Shanghai Yunyi Health Technology Development Co Ltd Neoplasms Details
MEDI-5752 MEDI-5752 Phase 1 Clinical Medimmune Llc Solid tumours; Carcinoma, Renal Cell Details
RO-7247669 RO-7247669 Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Liver Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
T3011 MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV Phase 2 Clinical Immvira Co Ltd Breast Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lymphoma; Lung Neoplasms; Colorectal Neoplasms; Solid tumours; Sarcoma; Mesothelioma; Skin Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Head and Neck Neoplasms; Ovarian Neoplasms; Liver Neoplasms Details
PD-1 knockout engineered T cells (Chengdu MedGenCell) Phase 2 Clinical West China Hospital Of Sichuan University, Chengdu Medgencell Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Pembrolizumab/Quavonlimab MK-1308A Phase 3 Clinical Merck Sharp & Dohme Corp, Msd Ireland (Carlow), Moshadong R & D (China) Co Ltd Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma Details
PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) Phase 2 Clinical Anhui Korton Biological Technology Co Ltd, Hangzhou Cancer Hospital Esophageal Neoplasms Details
Zeluvalimab AMG-404 Phase 2 Clinical Amgen Inc Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Vudalimab XmAb-20717; XmAb-717 Phase 2 Clinical Xencor Inc Carcinoma, Neuroendocrine; Vulvar Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Adenocarcinoma, Clear Cell; Colorectal Neoplasms; Astrocytoma; Carcinoma, Squamous Cell; Thymoma; Breast Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Biliary Tract Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms, Castration-Resistant; Adnexal Diseases; Mesothelioma; Adenoma, Acidophil; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Ovarian Neoplasms; Solid tumours Details
Mavezelimab/Pembrolizumab MK-4280A; MK-4820A Phase 3 Clinical Msd Ireland (Carlow) Merck Sharp & Dohme Corp, Moshadong R & D (China) Co Ltd Solid tumours; Carcinoma, Renal Cell; Hodgkin Disease; Small Cell Lung Carcinoma; Colorectal Neoplasms Details
Iparomlimab/Tuvonralimab QL-1706; PSB-205; PBS-103/PBS-105 Phase 3 Clinical Qilu Pharmaceutical Co Ltd Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Spartalizumab PDR-001 Phase 3 Clinical Novartis Pharma Ag Carcinoma, Pancreatic Ductal; Chordoma; Urinary Bladder Neoplasms; Uveal melanoma; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Cholangiocarcinoma; Colorectal Neoplasms; Primary Myelofibrosis; Gastrointestinal Stromal Tumors; Bone Marrow Diseases; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Prostatic Neoplasms, Castration-Resistant; Lung Neoplasms; Lymphoma; Sarcoma, Alveolar Soft Part; Leukemia, Myeloid, Acute; Esophageal adenocarcinoma; Uterine Neoplasms; Metastatic breast cancer; Thyroid Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Adenocarcinoma; Persistent Fetal Circulation Syndrome; Carcinoma, Endometrioid; Triple Negative Breast Neoplasms; Ovarian Neoplasms; Liver Neoplasms; Leukemia, Myeloid; Leukemia; Head and Neck Neoplasms; Kidney Neoplasms; Preleukemia; Hematologic Diseases; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms Details
TC-510 TC-510 Phase 2 Clinical Tcr2 Therapeutics Inc Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Mesothelioma; Colorectal Neoplasms; Adenocarcinoma Details
Pembrolizumab/Vibostolimab MK-7684A Phase 3 Clinical Merck & Co Inc Ovarian Neoplasms; Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Endometrial Neoplasms; Gallbladder Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms Details
Ezabenlimab BI-754091 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Head and Neck Neoplasms; Solid tumours; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma Details
Carrelizumab Phase 3 Clinical Beijing Chest Hospital Stomach Neoplasms; Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Sasanlimab PF-06801591; PF-6801591; RN-888 Phase 3 Clinical Pfizer Pharmaceuticals Ltd (China) Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Bile Duct Neoplasms; Prostatic Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Solid tumours; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Carcinoma, Renal Cell; Liver Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms Details
Cetrelimab JNJ-63723283; JNJ-3283 Phase 3 Clinical Johnson & Johnson Hepatitis B, Chronic; Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Prostatic Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Small Cell Details
Retifanlimab INCMGA-0012; INCMGA-00012; MGA-012 Phase 3 Clinical Macrogenics Inc Esophageal adenocarcinoma; Prostatic Neoplasms; Sarcoma; Lymphoma, Follicular; Breast Neoplasms; Astrocytoma; Colorectal Neoplasms; Glioma; Endometrial Neoplasms; Carcinoma, Pancreatic Ductal; Urinary Bladder Neoplasms; Carcinoma, Squamous Cell; Penile Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Melanoma; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Anus Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell; Ovarian Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Glioblastoma; Oligodendroglioma; Liposarcoma Details
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell Details
INCA-32459 INCA-32459 Phase 1 Clinical Incyte Corp, Merus Nv Neoplasms Details
Ivonescimab AK-112 Phase 3 Clinical Zhongshan Akeso Biopharma Co Ltd Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Endometrial Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular Details
LZM-009 LZM-009 Phase 2 Clinical Livzon(Group) Pharmaceutical Factory Solid tumours; Thymoma; Carcinoma, Non-Small-Cell Lung Details
MW-11 MW-11; 9MW1111; 9-MW1111; 9MW-1111; 9-MW-1111 Phase 1 Clinical Mabwell (Shanghai) Bioscience Co Ltd Solid tumours; Breast Neoplasms Details
Acrixolimab YBL-006; YBL 006 Phase 2 Clinical Y-biologics Inc Solid tumours; Neoplasms Details
IBI-319 IBI-319 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Neoplasms Details
IBI-321 IBI-321 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
PH-762 PH-762 Phase 1 Clinical Phio Pharmaceuticals Corp Breast Neoplasms; Melanoma Details
Pidilizumab MDV-9300; CT-011 Phase 2 Clinical Curetech Ltd Ovarian Neoplasms; Carcinoma, Renal Cell; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Colonic Neoplasms; Multiple Myeloma; Prostatic Neoplasms; Sarcoma; Breast Neoplasms; Colorectal Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Carcinoma, Hepatocellular; Hepatitis C, Chronic Details
Reozalimab IBI-318; LY-3434172; LY3434172 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details
Fidasimtamab IBI-315 Phase 1 Clinical Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
Nofazinlimab CS-1003 Phase 3 Clinical Cstone Pharmaceuticals Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) 609-A; SSGJ-609A; SSGJ-609-A Phase 2 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Solid tumours; Sarcoma; Breast Neoplasms Details
AZD-7789 AZD-7789 Phase 2 Clinical AstraZeneca Ag Hodgkin Disease; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message